Cno Financial Group . 5.125 Earnings Calls
| Release date | Jul 28, 2025 |
| EPS estimate | $0.86 |
| EPS actual | $0.93 |
| EPS Surprise | 8.89% |
| Revenue estimate | 747.808M |
| Revenue actual | 1.152B |
| Revenue Surprise | 53.98% |
| Release date | Apr 28, 2025 |
| EPS estimate | $0.790 |
| EPS actual | $0.133 |
| EPS Surprise | -83.18% |
| Revenue estimate | 755.052M |
| Revenue actual | 1.004B |
| Revenue Surprise | 32.98% |
| Release date | Dec 30, 2023 |
| EPS estimate | - |
| EPS actual | $0.319 |
| Revenue estimate | - |
| Revenue actual | 1.155B |
| Release date | Jun 29, 2023 |
| EPS estimate | - |
| EPS actual | $0.637 |
| Revenue estimate | - |
| Revenue actual | 1.023B |
Last 4 Quarters for Cno Financial Group . 5.125
Below you can see how CNO-PA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jun 29, 2023 |
| Price on release | $15.69 |
| EPS estimate | - |
| EPS actual | $0.637 |
| Date | Price |
|---|---|
| Jun 23, 2023 | $15.33 |
| Jun 26, 2023 | $15.45 |
| Jun 27, 2023 | $15.50 |
| Jun 28, 2023 | $15.74 |
| Jun 29, 2023 | $15.69 |
| Jun 30, 2023 | $16.00 |
| Jul 03, 2023 | $16.10 |
| Jul 05, 2023 | $16.10 |
| Jul 06, 2023 | $15.75 |
| 4 days before | 2.35% |
| 4 days after | 0.382% |
| On release day | 1.98% |
| Change in period | 2.74% |
| Release date | Dec 30, 2023 |
| Price on release | $17.42 |
| EPS estimate | - |
| EPS actual | $0.319 |
| Date | Price |
|---|---|
| Dec 22, 2023 | $17.52 |
| Dec 26, 2023 | $17.69 |
| Dec 27, 2023 | $17.74 |
| Dec 28, 2023 | $17.65 |
| Dec 29, 2023 | $17.42 |
| Jan 02, 2024 | $17.40 |
| Jan 03, 2024 | $17.10 |
| Jan 04, 2024 | $16.92 |
| Jan 05, 2024 | $16.96 |
| 4 days before | -0.571% |
| 4 days after | -2.64% |
| On release day | -0.115% |
| Change in period | -3.20% |
| Release date | Apr 28, 2025 |
| Price on release | $17.61 |
| EPS estimate | $0.790 |
| EPS actual | $0.133 |
| EPS surprise | -83.18% |
| Date | Price |
|---|---|
| Apr 22, 2025 | $17.17 |
| Apr 23, 2025 | $17.28 |
| Apr 24, 2025 | $17.28 |
| Apr 25, 2025 | $17.41 |
| Apr 28, 2025 | $17.61 |
| Apr 29, 2025 | $17.65 |
| Apr 30, 2025 | $17.28 |
| May 01, 2025 | $17.44 |
| May 02, 2025 | $17.82 |
| 4 days before | 2.59% |
| 4 days after | 1.17% |
| On release day | 0.202% |
| Change in period | 3.79% |
| Release date | Jul 28, 2025 |
| Price on release | $18.96 |
| EPS estimate | $0.86 |
| EPS actual | $0.93 |
| EPS surprise | 8.89% |
| Date | Price |
|---|---|
| Jul 22, 2025 | $18.34 |
| Jul 23, 2025 | $18.41 |
| Jul 24, 2025 | $18.80 |
| Jul 25, 2025 | $18.83 |
| Jul 28, 2025 | $18.96 |
| Jul 29, 2025 | $19.20 |
| Jul 30, 2025 | $18.94 |
| Jul 31, 2025 | $19.66 |
| Aug 01, 2025 | $19.65 |
| 4 days before | 3.38% |
| 4 days after | 3.64% |
| On release day | 1.27% |
| Change in period | 7.14% |
Cno Financial Group . 5.125 Earnings Call Transcript Summary of Q2 2025
CNO reported a strong Q2 2025 driven by record sales and continued distribution momentum. Total new annualized premiums (NAP) hit $120 million (up 17% YoY) and annuity collected premiums set a new quarterly record, surpassing $500 million (up 19%). Operating earnings per diluted share were $0.87, and insurance product margins benefited from rising book yields and favorable claims experience across most products. New money rates have exceeded 6% for 10 consecutive quarters and book yield and invested assets grew for the 12th straight quarter, while alternative investment returns (6%) remain below the long-term target (9–10%). The company returned $117 million to shareholders in the quarter via buybacks (reducing diluted shares by ~8%) and ended the quarter with a consolidated RBC of 378% and Holdco liquidity of $187 million. Management reaffirmed full-year guidance (with a slight tightening to the expense ratio upper bound to 19.2%) and reiterated a run-rate operating ROE target of ~10.5% for 2025 and a 3-year target of 11.5% for 2027. Business highlights include double-digit growth across Consumer and Worksite divisions, strong direct-to-consumer digital growth (web/digital ~1/3 of D2C sales, +39% YoY), improving agent productivity and recruiting, targeted rate filings for Medicare Supplement (~10% average requested), and ongoing investments in technology and distribution to sustain long-term middle‑income market penetration.
Sign In
Buy CNO-PA